Marty, I could be wrong, but I think the reasons Paulson may not take another bite involves reputation and credibility. After all, another round with at or near the current SP, even with warrants, isn't a compelling proposition to present to investors. Further, I don't think CYDY is in a position to secure debt capital, so, by default, management has limited options. That said, an attractive licensing deal is feasible and a reasonable solution for short term and long term capital challenges. Whatever path is taken, IMO, it must be a comprehensive solution to securing funds to finish the trials. A piecemeal approach has been okay and has gotten the company this far, but I don't think it's the best choice moving forward.
News 
Market Data 
Discover 
AI
